Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS

dc.creatorAraújo-Mariz, Carolline
dc.creatorLopes, Edmundo Pessoa
dc.creatorAcioli-Santos, Bartolomeu
dc.creatorMaruza, Magda
dc.creatorMontarroyos, Ulisses Ramos
dc.creatorXimenes, Ricardo Arraes de Alencar
dc.creatorLacerda, Heloísa Ramos
dc.creatorMiranda-Filho, Demócrito de Barros
dc.creatorAlbuquerque, Maria de Fátima Pessoa Militão de
dc.date2017-06-07T18:36:43Z
dc.date2017-06-07T18:36:43Z
dc.date2016
dc.date.accessioned2023-09-26T23:26:36Z
dc.date.available2023-09-26T23:26:36Z
dc.identifierARAÚJO-MARIZ, Caroline et al. Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS. Plos One, v. 11, n. 6, p. 1-15, 22 jun. 2016.
dc.identifier1932-6203
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/19342
dc.identifier10.1371/journal.pone.0157725
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8890612
dc.descriptionHepatotoxicity is frequently reported as an adverse reaction during the treatment of tuberculosis. The aim of this study was to determine the incidence of hepatotoxicity and to identify predictive factors for developing hepatotoxicity after people living with HIV/AIDS (PLWHA) start treatment for tuberculosis. This was a prospective cohort study with PLWHA who were monitored during the first 60 days of tuberculosis treatment in Pernambuco, Brazil. Hepatotoxicity was considered increased levels of aminotransferase, namely those that rose to three times higher than the level before initiating tuberculosis treatment, these levels being associated with symptoms of hepatitis. We conducted a multivariate logistic regression analysis and the magnitude of the associations was expressed by the odds ratio with a confidence interval of 95%. Hepatotoxicity was observed in 53 (30.6%) of the 173 patients who started tuberculosis treatment. The final multivariate logistic regression model demonstrated that the use of fluconazole, malnutrition and the subject being classified as a phenotypically slow acetylator increased the risk of hepatotoxicity significantly. The incidence of hepatotoxicity during treatment for tuberculosis in PLWHA was high. Those classified as phenotypically slow acetylators and as malnourished should be targeted for specific care to reduce the risk of hepatotoxicity during treatment for tuberculosis. The use of fluconazole should be avoided during tuberculosis treatment in PLWHA.
dc.formatapplication/pdf
dc.languageeng
dc.rightsopen access
dc.subjectTuberculose
dc.subjectHepatotoxicidade
dc.subjectHIV
dc.subjectAIDS
dc.subjectSíndrome de Imunodeficiência Adquirida / complicações
dc.subjectAntituberculosos / efeitos adversos
dc.subjectAntituberculosos / uso terapêutico
dc.subjectLesão Hepática Induzida por Substâncias Químicas e Medicamentosas / patologia
dc.subjectTuberculose / complicações
dc.subjectTuberculose / quimioterapia
dc.titleHepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS
dc.typeArticle


Este ítem pertenece a la siguiente institución